| Literature DB >> 28807909 |
Robert T Schooley1, Biswajit Biswas2,3, Jason J Gill4,5, Adriana Hernandez-Morales6, Jacob Lancaster5, Lauren Lessor5, Jeremy J Barr7,8, Sharon L Reed9,10, Forest Rohwer7, Sean Benler7, Anca M Segall7, Randy Taplitz9, Davey M Smith9, Kim Kerr9, Monika Kumaraswamy9, Victor Nizet11,12, Leo Lin11, Melanie D McCauley9, Steffanie A Strathdee9, Constance A Benson9, Robert K Pope13, Brian M Leroux13, Andrew C Picel14, Alfred J Mateczun2, Katherine E Cilwa15, James M Regeimbal2, Luis A Estrella2, David M Wolfe2, Matthew S Henry2,3, Javier Quinones2,3, Scott Salka16, Kimberly A Bishop-Lilly2,3, Ry Young5,6, Theron Hamilton2.
Abstract
Widespread antibiotic use in clinical medicine and the livestock industry has contributed to the global spread of multidrug-resistant (MDR) bacterial pathogens, including Acinetobacter baumannii We report on a method used to produce a personalized bacteriophage-based therapeutic treatment for a 68-year-old diabetic patient with necrotizing pancreatitis complicated by an MDR A. baumannii infection. Despite multiple antibiotic courses and efforts at percutaneous drainage of a pancreatic pseudocyst, the patient deteriorated over a 4-month period. In the absence of effective antibiotics, two laboratories identified nine different bacteriophages with lytic activity for an A. baumannii isolate from the patient. Administration of these bacteriophages intravenously and percutaneously into the abscess cavities was associated with reversal of the patient's downward clinical trajectory, clearance of the A. baumannii infection, and a return to health. The outcome of this case suggests that the methods described here for the production of bacteriophage therapeutics could be applied to similar cases and that more concerted efforts to investigate the use of therapeutic bacteriophages for MDR bacterial infections are warranted.Entities:
Keywords: Acinetobacter; bacteriophage therapy; multidrug resistance
Mesh:
Substances:
Year: 2017 PMID: 28807909 PMCID: PMC5610518 DOI: 10.1128/AAC.00954-17
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191